Megan Brooks on Muck Rack

Megan Brooks

  • Writer and Editor, Freelance
  • Freelance Journalist, Medscape
  • None, Freelance, Medscape
  • None, Freelance (Medscape)
Weston
As seen in: Medscape, Business Insider, Daily Mail, HuffPost, Reuters, WebMD, Scientific American, The Globe and Mail, Flipboard, Medscape Duestch, Medscape France and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Megan

Contact Megan, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Better Test for Finding Residual Pancreatic Cancer?

|
By Megan Brooks
| Medscape Verified
A highly sensitive circulating tumor DNA (ctDNA) assay directed at KRAS mutations can detect residual disease in substantially more patients with localized pancreatic cancer than standard next-generation sequencing (NGS), a prospective study showed. Researchers found that digital droplet polymerase chain reaction (ddPCR) targeting three common KRAS mutations identified ctDNA in nearly four times as many patients as standard NGS at diagnosis.
Open in Who Shared Issue with article?

GLP-1s for Addiction: Are We There Yet?

|
By Megan Brooks
| Medscape Verified
Substance use disorders (SUDs) may become the next therapeutic target for GLP-1 receptor agonists (GLP-1s). Although the evidence remains preliminary, growing preclinical, observational, and early clinical data suggest these drugs may reduce the cravings that drive addiction. Interest has accelerated over the past few years, fueled by reports that patients taking semaglutide or tirzepatide for diabetes or obesity drink less alcohol, smoke fewer cigarettes, or experience fewer cravings.
Open in Who Shared Issue with article?

Agonistas del receptor del péptido 1 similar al glucagón para la adicción: ¿una opción plausible?

|
By Megan Brooks
| Medscape Noticias Médicas Verified
Los trastornos por consumo de sustancias podrían convertirse en el próximo objetivo terapéutico de los agonistas del receptor del péptido 1 similar al glucagón (GLP-1). Aunque la evidencia sigue siendo preliminar, los datos preclínicos, observacionales y clínicos tempranos sugieren que estos fármacos podrían reducir los antojos que impulsan la adicción.
Open in Who Shared Issue with article?
See all 4,438 licensed articles (4,463 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified